水凝药物输送系统对治疗性结肠炎的影响:临床前的元分析
Lan Jiang1, Jia Li2, Runkun Yang3
1Center for Drug Safety Evaluation and Research, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310007, China; Taizhou Institute of Zhejiang University, Zhejiang university, Taizhou 318000, China.
International journal of pharmaceutics
|May 27, 2024
概括
与免费药物相比,水凝药物递送系统 (DDS) 在性结肠炎 (UC) 治疗中显示出更高的有效性. 通过口服给药的水凝DDS被证明是优越的,突出了它们在肠道向药物输送方面的潜力.
科学领域:
- 生物材料科学 生物材料科学
- 药品制造 药品制造 药品制造
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 治疗存在挑战,水凝药物递送系统 (DDS) 正成为一个有前途的治疗方法.
- 缺少针对UC的水凝DDS的临床前证据的全面摘要,需要进行元分析.
研究的目的:
- 进行一项元分析,评估水凝DDS与性结肠炎 (UC) 免费药物管理相比的疗效.
- 根据水凝材料成分 (多糖与非多糖) 和施用途径 (口服与直肠) 进行子组分析.
主要方法:
- 对临床前研究进行系统的元分析,将水凝DDS与UC的免费药物管理进行比较.
- 评估结果包括结肠长度,组织学分数,瘤亡因子-α (TNF-α),zonula occludens蛋白1 (ZO-1) 和曲线下面积 (AUC).
- 根据水凝材料类型和施用途径分层分类的子组分析.
主要成果:
- 与免费药物组相比,Hydrogel DDSs对UC表现出显著的治疗增强.
- 在多糖和非多糖水凝材料之间没有观察到有效性的显著差异.
- 与直肠给药相比,口服水凝DDS在改善TNF-α水平和AUC方面表现优越.
结论:
- 口服水凝DDS代表了在UC中对结肠向药物递送的高度有效的剂量形式.
- 在UC水凝DDS设计的背景下,基于多糖的水凝在其他材料上没有显著的优势.
- 这些发现支持进一步开发口服水凝DDS用于治疗性结肠炎.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
408
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
408
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
01:17Drugs for Treatment of Diarrhea-Predominant IBS
160
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
160
01:26Peptic Ulcer Disease IV: Management
88
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
88